Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

November 24, 2015

The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

Previous Article
Breast Center of Acadiana to deploy Sectra Breast Imaging PACS in two freestanding imaging centers
Breast Center of Acadiana to deploy Sectra Breast Imaging PACS in two freestanding imaging centers

International medical imaging IT company Sectra announces that Breast Center of Acadiana has entered into ...

Next Article
New collaboration aims to develop novel generation artificial pancreas
New collaboration aims to develop novel generation artificial pancreas

Debiotech SA, the ARTORG Center for Biomedical Engineering Research of the University of Bern - and the Div...